This finding suggests that Parp1 deletion or Parp inhibition may not give rise to the same outcomes across all tissues and experimental models, making it increasingly important to consider the clinical consequences of PARP inhibition in cancer treatment. The gene discussed is PARP1; the disease is cancer.